News

Aethlon Medical Reports Fiscal Q4 Results and Updates

Aethlon Medical Reports Fiscal Q4 Results and Updates

Aethlon Medical Shares Fourth Quarter Financial Results

Aethlon Medical, Inc. (NASDAQ: AEMD), a company dedicated to advancing innovative treatments for cancer and infectious diseases, has provided an encouraging overview of its financial results for the recently concluded fiscal fourth quarter. Active efforts in their Hemopurifier® cancer trial are underway, which includes the treatment of three patients. The organization has also made significant strides in its operational efficiency, cutting down on expenses while expanding its research focus.

Key Highlights from the Fiscal Year

During this fiscal period, several critical achievements stand out:

  • The first three patients were treated in the Hemopurifier® cancer trial at designated Australian sites.
  • A regulatory nod was received from India's Central Drugs Standard Control Organization to initiate similar oncology trials.
  • The study’s protocol is under review to align with the evolving standards of immunotherapy practices.
  • Impressive preclinical data showcased a 98.5% efficacy in removing platelet-derived extracellular vesicles via simulated Hemopurifier® treatments.
  • A promising collaboration with UCSF is set to explore Long COVID implications, with insights to be unveiled at an upcoming symposium.
  • Operating costs saw a substantial reduction due to optimized operations.

Clinical Advancements in Cancer Treatment

As part of Aethlon's commitment to expanding treatment options, the company recently recorded its first successful treatments involving the Hemopurifier. The initial three participants in the trial were carefully selected to engage in a comprehensive study focused on safety and feasibility for patients exhibiting solid tumors that have shown resistance to conventional anti-PD-1 therapies.

The trial's first participant commenced treatment at a leading hospital, with subsequent treatments administered promptly to others. Following their treatments, all subjects successfully completed a rigorous 7-day safety follow-up, thereby meeting necessary regulatory checkpoints. An independent Data Safety Monitoring Board (DSMB) now convenes to assess the safety data and strategize on advancing to the next treatment cohort.

This next set of participants will be involved in a two-treatment regimen spaced within a week, allowing for a deeper understanding of the Hemopurifier’s effects on tumor response. Preliminary findings are anticipated within a three-month window, particularly regarding how the Hemopurifier® influences extracellular vesicle extraction and T-cell activity.

To stay current with therapeutic standards, the trial protocol has also been adjusted to broaden patient eligibility, now including individuals receiving combination therapies with Pembrolizumab or Nivolumab. This adaptive approach is crucial, especially considering that only a small percentage of patients typically show enduring responses to those medications.

Regulatory Approval in India

In another significant development, Aethlon has received formal regulatory approval from India to commence a similar trial. This approval, granted by the CDSCO, follows rigorous discussions and requisite clearance from ethical committees. Plans are in motion to start the trial at Medanta Medicity Hospital shortly, guided by a local contract research organization.

Preclinical Insights Inform Future Directions

A recent peer-reviewed study highlighted the efficacy of the Hemopurifier in removing extracellular vesicles implicated in various diseases, including enhancements in potential therapeutic avenues across multiple disorders. This research strengthens Aethlon's foundation as it forges ahead with its clinical trials while suggesting that the Hemopurifier could be beneficial beyond its initial cancer focus.

Scientific Collaborations and Operational Efficiency

Collaboration with UCSF has moved forward as Aethlon engages in research targeting Long COVID, which affects millions. Their commitment to understanding the condition's complexities underscores the company’s dedication to addressing pressing medical needs.

The year 2025 has seen a pronounced decline in operating expenses, allowing Aethlon to concentrate its resources on clinical and regulatory initiatives. The company reported a cash balance nearing $5.5 million as of the end of the fourth quarter. Overall operational expenses were registered at approximately $9.3 million for the fiscal year, reflecting a significant reduction compared to previous periods.

Looking Ahead: Financial Overview and Conference Call

Management has announced a scheduled conference call intended to delve deeper into the financial results and provide context on the company's strategic directions. Stakeholders are encouraged to participate, as Aethlon aims to clarify operational advancements and reinforce its ongoing commitment to innovation in medical solutions.

Frequently Asked Questions

What are Aethlon Medical's main focuses in its research?

Aethlon Medical is primarily focused on developing treatments for cancer, Long COVID, and life-threatening viral infections using their Hemopurifier technology.

How has Aethlon reduced its operational expenses?

The company has achieved significant cost reductions through streamlined operations and efficient management of resources, including a recent workforce realignment.

What are the implications of the Indian regulatory approval?

The approval allows Aethlon to proceed with its Hemopurifier trials in India, expanding its geographical footprint and potential patient reach.

What results are expected from the Hemopurifier trials?

Preliminary data regarding safety and efficacy is expected to emerge within three months, focusing on the device's impact on tumor response and immune activity.

How can stakeholders stay informed about Aethlon Medical?

Stakeholders can stay updated by participating in conference calls, reviewing financial reports, and visiting the company's website for new information on research and development initiatives.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

A. O. Smith's Sustainability Scorecard Has Real Teeth

Updated Category News Views 116

Numbers finally showed up wearing work boots in A. O. Smith’s latest sustainability report. The company says it beat every one of its three environmental targets, and the gaps were not the sort of rounding-error victories corporate communications teams love to polish until they shine. For investors following NYSE:AOS, that deserves a look—not a standing ovation, but a...

Continue Reading
NetEase Miss Opens an Investigation, Not a Verdict

Updated Category News Views 37

A two-dollar earnings gap can make a shareholder base jumpy fast, and NetEase just handed the market a rough set of numbers to chew on. The November 19 notice says NetEase's third-quarter 2026 report missed Wall Street expectations on both earnings and revenue, followed by a sharp decline in the shares. That has prompted SueWallSt, powered by Levi & Korsinsky LLP, to...

Continue Reading
DHC’s Ulta Rollout Gets a Useful Pricing Correction

Updated Category News Views 32

A face-wash price tag just became the most revealing part of DHC’s Ulta expansion. The company corrected an earlier announcement that had listed its new Deep Cleansing Face Wash at $31.50; the actual price is $19.00. That may sound like tiny housekeeping, and in the grand scheme it is, but consumer brands live or die on this kind of detail. A cleanser priced near $20...

Continue Reading
Institutions Spread AI Bets as 2027 Risks Mount Higher

Updated Category News Views 89

Money managers are not fleeing the party; they are checking the fire exits. Natixis Investment Managers surveyed 515 institutions overseeing $42.7 trillion, and their 2027 posture is pretty plain: keep taking risk, just stop pretending every risk is the same. Inflation, rates, government debt, geopolitical fracture and an AI spending boom are all tugging at portfolios at...

Continue Reading
First Grade Literacy Push Deserves a Harder Look Now

Updated Category News Views 130

A reading gap can become a concrete wall before anyone bothers measuring it. That is the uncomfortable point behind Ignite Reading's First Grade Promise, and it deserves more attention than another polished education announcement usually gets. At a Nov. 5 Convene 2026 gathering in Boston, 56 district and literacy leaders from six states focused on getting children reading...

Continue Reading
IQSTEL’s 2027 Plan Has Scale but Still Needs Proof

Updated Category News Views 46

A $313 million nine-month revenue figure gets attention, yet this story is really about whether IQSTEL can finally turn a big telecom pipe into money that sticks. The company grew consolidated revenue 34.5% year over year through September 30, 2026, and third-quarter revenue hit $106.0 million, its second straight quarter above $100 million. That is real operating scale,...

Continue Reading
Royce Global Trust's Discount Is Still the Whole Debate

Updated Category News Views 90

A $3.03 gap is staring investors right in the face. As of October 31, 2026, Royce Global Trust carried a net asset value of $17.51 per share while the market price sat at $14.48. That works out to roughly a 17.3% discount to NAV, and with a closed-end fund, that discount is not some footnote shoved under the table. It is a major part of the return story, good or bad. The...

Continue Reading
GomSpace's €8M Lunar Deal Pushes Mission Ambitions

Updated Category News Views 83

Moon hardware is where small-space dreams either grow teeth or chew through cash, and GomSpace has just taken another meaningful bite. The company has secured an €8 million, or 89.1 million Swedish kronor, contract for the second phase of a lunar mission program with an unnamed leading North American space company. For GOMX, this is not some vague laboratory...

Continue Reading
Cirrus CEO Takes SIA Chair as Chip Policy Heats Up

Updated Category News Views 114

A trade-group gavel rarely moves a stock by itself, but this one lands in a noisy part of the chip cycle. On November 19, 2026, the Semiconductor Industry Association elected Cirrus Logic President and CEO John Forsyth as chair of its board. That is not a revenue announcement, not a factory groundbreaking, and certainly not a reason to start flinging confetti at...

Continue Reading
Makers Nutrition Backs Families Through Friends of Karen

Updated Category News Views 79

A thousand dollars in gift cards can look modest beside the noise of holiday marketing, but it lands differently when a family is carrying the weight of a child’s life-threatening illness. Makers Nutrition, a Hauppauge, New York-based private-label and custom supplement manufacturer, has donated $1,000 in gift cards to Friends of Karen for the nonprofit’s annual...

Continue Reading

Top 5 Most Recently Viewed Articles

Immuron Advances IMM-529 Development Following FDA Feedback

Updated Category News Views 289

Immuron Charts Path for Phase 2 Trial of IMM-529 Key Highlights Immuron concludes an important pre-IND meeting with the FDA regarding IMM-529, aimed at combating Clostridioides difficile infection (CDI). Previous clinical trials highlight the necessity for ongoing development of IMM-529. The company plans to submit an IND application for IMM-529 in the first half of 2025.

Continue Reading
Enefit Green to Host Webinars for Unveiling 2024 Results

Updated Category News Views 123

Join Enefit Green's Upcoming Webinars on 2024 Results Enefit Green is set to announce its Q4 and annual unaudited results for 2024. The special reveal will occur shortly after the publication of the report, allowing shareholders and investors to gain critical insights into the company's financial standing. Webinar Schedule and Details The webinars will be hosted on the...

Continue Reading
Intapp's Encouraging Earnings Fuel Stock Surge Amid Market Momentum

Updated Category News Views 197

Intapp's Strong Earnings Report Captivates Investors On a positive note for investors, U.S. stocks saw an uplifting day, with the Dow Jones index climbing approximately 250 points. The highlight of the day was the impressive performance of Intapp, Inc. Shares of Intapp, Inc. (NASDAQ: INTA) experienced a sharp increase following the company's announcement of...

Continue Reading
NewAmsterdam Pharma's Upcoming Conference Participation for 2024

Updated Category News Views 229

NewAmsterdam Pharma Announces Conference Participation NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) is gearing up for an exciting lineup of presentations at key medical and investor conferences. As a leader in developing innovative oral therapies for cardiovascular disease, NewAmsterdam is set to share groundbreaking research findings and engage with stakeholders in...

Continue Reading
John Hancock Funds Announce Monthly Distribution Updates

Updated Category News Views 366

Monthly Distribution Announcements from John Hancock Funds John Hancock has announced important updates regarding the distributions for its closed-end funds. These monthly distributions aim to provide returns to investors, ensuring they receive value from their investments in a timely manner. Details of the Monthly Distribution Declaration Key Dates Recently, the board of...

Continue Reading